Matrix Laboratories Limited

New Document

Financial Year 2007 - 2008

Quarter IV
(March 2008)

Quarter III
(December 2007)

Quarter II
(September 2007)

Quarter I
(June 2007)

Financial Year 2006 - 2007

Quarter IV
(March 2007)

Quarter III
(December 2006)

Quarter II
(September 2006)

Quarter I
(June 2006)
Financial Year 2005 - 2006

Quarter III
(December 2005)

Quarter II
(September 2005)

Quarter I
(June 2005)

Financial Year 2004 - 2005

Quarter IV
(March 2005)

Quarter III
(December 2004)

Quarter II
(September 2004)

Quarter I
(June 2004)

Financial Year 2003 - 2004

Quarter IV
(March 2004)

Quarter III
(December 2003)

Quarter II
(September 2003)

Quarter I
(June 2003)

Financial Year 2002 - 2003

Quarter IV
(March 2003)

Quarter III
(December 2002)

Quarter II
(September 2002)

Quarter I
(June 2002)

MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2004

(Rs.in Million )
Sl. No	Particulars	"Quarter ended 31st March"		"Year ended 31st March 2004 (Un audited)"	"Year Ended 31st March 2003 (Audited)"
		2004 (Un audited)	2003 (Un audited)
	Gross Sales - Exports - Domestic	1470.84 845.08 625.76	852.80 725.46 127.34	5604.27 3104.02 2500.25	4169.27 2888.47 1280.80
01. 02. 03. 04. 05. 06. 07. 08. 09. 10. 11. 12. 13. 14. 15 16	Net Sales Other Income Total Expenditure a) (Increase) / Decrease in Stock b) Consumption of Raw materials c) Staff Cost d) Other Expenditure Interest Depreciation Profit before Tax (1+2-3-4-5) Provision for Tax - Current - Deferred Profit after Tax (6-7-8) Prior period adjustments including taxes Profit after Tax and adjustments (9-10) Equity Capital (fully paid up Rs. 10 each) Share Capital suspense Reserves excluding revaluation reserves Basic E.P.S in Rs. Diluted E.P.S in Rs. **(Not Annualised for the quarter ) Aggregate of Non promoters Shareholding Number of shares Percentage of Shareholding	1414.63 33.14 903.10 (145.43) 712.05 49.01 287.47 88.84 29.26 426.57 33.00 5.00 388.57 4.28 384.29 123.03 - 31.25 29.45 6797134 55.27%	833.24 0.05 438.68 (49.49) 263.83 20.53 203.81 14.09 6.71 373.81 29.00 7.50 337.31 0.07 337.24 97.18 - 44.38 33.13 4430164 45.59%	5374.46 62.31 3591.46 (407.95) 2695.26 201.68 1102.47 152.65 110.45 1582.21 148.00 85.00 1349.21 2.91 1346.30 123.03 - 109.47 107.84 6797134 55.27%	3990.30 7.72 2709.98 21.61 1672.08 142.24 874.05 260.39 71.96 955.69 57.00 147.24 751.45 0.91 750.54 97.18 25.79 892.62 98.78 73.74 4430164 45.59%

Notes :

1. The above Unaudited Financial Results were considered and approved by the Board of Directors at their meeting held on 24th April 2004.

2. The figures for the corresponding quarter ended 31st March 2003 are that of Matrix Laboratories Limited without considering the results of Medicorp Technologies India Limited and Vorin Laboratories Limited amalgamated from 1st April 2002 and to that extent not comparable.

3. The activities of the Company relate to only one segment i.e. Pharmaceuticals.

4. The Board of Directors at their meeting held on 29th March 2004 have approved the Scheme of Arrangement for Amalgamation of Vera Laboratories Limited (Vera), Fine Drugs and Chemicals Limited (FDCL) , Medikon Laboratories Limited (Medikon) and Calibre Engineering Pvt. Limited ( Calibre ) into Matrix Laboratories Limited (Matrix) from the appointed date 1st January 2004 in terms of which one fully paidup equity share of Rs. 10 each of Matrix will be alloted for every 163 equity shares of Rs.10 each of Vera , 25 equity shares of Rs.10 each of FDCL , 96 equity shares of Rs.10 each of Medikon and 8 equity shares of Rs.100 each of Calibre held by the shareholders in the respective companies subject to requisite approvals from shareholders and the Hon'ble High Court of Andhra Pradesh.

5. Pending statutory formalities, the financial results of the above four amalgamating companies are not combined with that of the company. Diluted EPS, however has been computed taking into account the equity shares to be issued to the shareholders of amalgamating companies as per the said Scheme.

6. Provision for Current Income Tax is computed after considering various deductions and setoff of brought forward losses / allowances of the amalgamating companies as permitted under the Income tax Act, 1961. Impact on Deferred Tax due to amalgamation has not been reckoned.

7. The Board of Directors at their meeting held on 15th April 2004 approved the proposed aggregate issue of 2250000 equity shares of Rs.10/- each at a price of Rs.1500/- per share on preferential basis to India Newbridge Investments Ltd. an investment vehicle of Newbridge Capital LLC and Maxwell (Mauritius) Pte Ltd an investment vehicle of Temasek Holdings (Private) Limited. The proposal is subject to approval by members at the ensuing extraordinary general meeting scheduled to be held on 15th May 2004.

8. Summary of Investor Complaints

Pending as on
01.01.2004 Received during
the Quarter Resolved Pending as on
31.03.2004

Nil 3 3 Nil

	For and on behalf of the Board
Place : Secunderabad Date : 24th April 2004	Sd/- N.PRASAD Chairman and Chief Executive Officer

Foote Page